Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Pirbright Institute currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 2 distinct examiners, which provides different examination perspectives the institute must address. However, both cases are situated within 1 distinct art unit, suggesting a consistent technical focus for the institute's current prosecution efforts.
BAO Q LI is the busiest examiner for the institute, currently overseeing 1 pending office action. Because there are 2 pending office actions in total, the workload is split between these officials. The institute's strategy must account for both examiners while operating within the constraints of the specified technical department. The focus on the Biotechnology & Pharmaceuticals sector within 1 distinct art unit indicates that while the examiners differ, the technical criteria for the active cases are likely similar.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17628286 | VACCINE | ALLEN, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17628286 | VACCINE | ALLEN, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17628286 | VACCINE | ALLEN, MICHAEL D | 1671 | §103§112 | Non-Final OA | — | Pending | Jan 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Pirbright Institute has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael D Allen has the most, with 1 of The Pirbright Institute's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
